SEOUL, South Korea (PRWEB)
October 21, 2022

Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has been selected as one of the promising AI startups in the ‘Korea AI Startup 100’ list for the second time in a row.

‘Korea AI Startup 100’, an annual accelerator project cohosted by the Korea Economic Daily and AI One Team, an Industry-University-Research Council, discovers promising Korean AI startups. The project aims to support companies to strengthen their market presence and build their capability, thus enhancing national AI competitiveness in the global market as well as boosting the establishment of the startup ecosystem.

To choose the most notable 100 startups, a committee made up of AI experts evaluated candidates based on criteria that the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute developed. The applicants were assessed on both quantitative factors such as market growth potential, corporate value, competitiveness in the AI technology space, and qualitative aspects including corporate sustainability.

After three rounds of evaluation, Deep Bio was selected as one of the finalists of the Korea AI Startup 100 in the healthcare industry. “It is a great honor to be designated as a promising startup that represents Korea. This opportunity once again becomes motivation for our company to advance our AI capability that can contribute to the society,” said Sun Woo Kim, the CEO of Deep Bio. He also added, “with our innovative deep learning technology, we will strive to lead the digitalization of medical care.”

Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute l purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).

Deep Bio also continues to build its global presence through overseas partnerships with digital pathology platform providers in the US, Europe, and India, as well as conduct research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.

About Deep Bio

Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.

DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores from 2019 to 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr

Share article on social media or email: